US Patent 8,796,307: Indacaterol Inhalation Capsule Claims, Patent Scope, Expiration, and Competitive Landscape

US Patent No. 8,796,307 protects pharmaceutical compositions containing indacaterol, particularly indacaterol maleate formulated as an inhalable dry powder in a capsule. The patent is composition-focused rather than directed primarily to the chemical compound, inhaler device, or manufacturing process. Its strongest commercial relevance is to capsule-based dry-powder products containing indacaterol maleate within the claimed dose range.

The claim set narrows from a capsule containing indacaterol or a salt or solvate to an inhalable dry powder, then to a daily dose of 1 to 5,000 micrograms, and finally to indacaterol maleate. A product that satisfies all limitations of claim 7 would face the most direct literal infringement exposure.

What drug and active ingredient does US Patent 8,796,307 cover?

The covered active ingredient is indacaterol, specifically the R-enantiomer:

(R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one

The patent also covers salts and solvates in claim 1. Claim 6 and claim 7 narrow the covered form to indacaterol maleate, the active pharmaceutical ingredient used in Arcapta Neohaler and other indacaterol products.

Indacaterol is a long-acting beta-2 adrenergic agonist, or LABA, administered by inhalation for maintenance treatment of airflow obstruction in chronic obstructive pulmonary disease. The FDA-approved Arcapta Neohaler product contains indacaterol maleate in inhalation capsules with a labeled dose of 75 micrograms once daily. The capsule is pierced by the Neohaler device and is not swallowed (FDA, 2011).

How do the claims of US 8,796,307 operate?

Claim structure

Claim	Required subject matter	Practical scope
1	Indacaterol or a salt or solvate, a pharmaceutically acceptable carrier, and a capsule	Broadest composition claim
2	Claim 1 composition in inhalable form	Excludes non-inhaled capsule products
3	Claim 2 composition in dry powder form	Targets dry-powder inhalation capsules
4	Claim 3 composition comprising a daily dose	Adds a dosing limitation without a numerical range
5	Claim 4 composition with a daily dose of 1 to 5,000 micrograms	Numerically defined dose range
6	Claim 1 composition in which the active is indacaterol maleate	Covers maleate capsule compositions
7	Claim 5 composition in which the active is indacaterol maleate	Narrowest express claim and closest to the marketed product

What does “comprising” mean in these claims?

The term “comprising” is open-ended. A composition can contain indacaterol, carrier material, and additional excipients or ingredients without falling outside the claim solely because other components are present.

A competing product does not avoid claim 1 merely by adding a second active ingredient, a different excipient, a stabilizer, or a different carrier. The product must instead avoid at least one required limitation, such as the capsule dosage form, the covered indacaterol form, or the claimed inhalable dry-powder configuration.

What does the capsule limitation require?

The capsule limitation is central. Claim 1 does not cover every indacaterol formulation. It requires the pharmaceutical composition to be “in the form of a capsule.”

The claim is directed to a product configuration in which the composition is contained in, or presented as, a capsule. A blister, cartridge, metered-dose inhaler canister, nebulizer reservoir, tablet, or injectable formulation would not satisfy the capsule limitation without additional facts establishing that the accused composition itself is in capsule form.

The patent therefore has less direct reach over:

Multidose dry-powder inhalers using a reservoir;
Metered-dose inhalers;
Nebulized indacaterol solutions;
Tablets or oral capsules not intended for inhalation;
Injectable or implantable dosage forms.

What formulations are protected by US 8,796,307?

The most commercially important protected formulation is a dry powder inhalation capsule containing indacaterol maleate and a pharmaceutically acceptable carrier.

The claims do not expressly identify lactose, but a lactose-based carrier commonly used in dry-powder inhalation products would generally fall within the carrier limitation if the remaining claim elements are met. The patent also does not require a particular capsule shell composition, inhaler device, particle-size distribution, blending process, or capsule-fill weight in the claims provided.

Formulation coverage by claim

Formulation characteristic	Claim coverage
Indacaterol free base	Covered by claim 1 if the other limitations are met
Indacaterol salt or solvate	Covered by claim 1
Indacaterol maleate	Specifically covered by claims 6 and 7
Pharmaceutically acceptable carrier	Required by every independent claim
Capsule dosage form	Required by claim 1 and all dependents
Inhalable product	Required by claims 2 through 5
Dry powder	Required by claims 3 through 5
1 to 5,000 microgram daily dose	Required by claims 5 and 7
Liquid nebulizer formulation	Not expressly covered by claims 2 through 5 and may not satisfy the capsule limitation
Tablet formulation	Not covered unless it is also a capsule composition meeting the claim language

How broad is the dose limitation?

Claim 5 covers a daily dose from 1 microgram to 5,000 micrograms. The range is broad and includes the 75-microgram labeled Arcapta dose.

Claim 4 is broader in one respect because it requires a daily dose but does not state a numerical range. Claim 5 is narrower because it adds the numerical limitation. Claim 7 combines the 1-to-5,000-microgram range with indacaterol maleate.

The dose limitation is potentially significant in generic litigation. A generic applicant could attempt to design around claims 5 and 7 by labeling a dose outside the range, but that strategy would not necessarily avoid claim 1 or claim 6. A court could also examine the actual composition, labeled use, dosing instructions, and induced-infringement theory rather than relying solely on the applicant’s proposed label.

Which claim is most relevant to Arcapta Neohaler?

Claim 7 is the closest match to the approved Arcapta Neohaler product:

Indacaterol maleate;
A pharmaceutically acceptable carrier;
A capsule;
An inhalable dry powder;
A daily dose within 1 to 5,000 micrograms.

The FDA-approved product uses a 75-microgram indacaterol maleate inhalation capsule administered once daily through the Neohaler device (FDA, 2011). On the facts stated in the approved labeling, the marketed product falls within the technical profile of claim 7.

The device itself is not the primary subject of these claims. A competitor using a different capsule-piercing inhaler could still face composition-claim exposure if its capsule contains the claimed indacaterol maleate dry-powder composition.

When does US Patent 8,796,307 lose exclusivity?

The patent issued on August 5, 2014. Its term is governed by the 20-year patent term measured from the applicable nonprovisional filing date, subject to patent-term adjustment and any patent-term extension. Public patent records identify an underlying 2005 priority framework for the indacaterol formulation technology, placing the ordinary term in approximately 2026 rather than 2034.

The precise enforceable expiration date must be determined from the USPTO patent record, including the patent-term-adjustment calculation and any terminal disclaimer. The grant date alone does not determine expiration.

Exclusivity timeline

Event	Timing
Indacaterol formulation patent family priority	2005 framework
US Patent 8,796,307 granted	August 5, 2014
Arcapta Neohaler FDA approval	July 1, 2011
Five-year new chemical entity exclusivity	Expired in 2016
Patent-based protection under US 8,796,307	Expected to extend into approximately 2026, subject to official PTA
Generic entry opportunity	After applicable patents and regulatory exclusivity are cleared

The five-year NCE period applied to indacaterol as a new active ingredient and is distinct from patent protection. FDA regulatory exclusivity and patent term do not expire on the same date.

What is the Orange Book status of US 8,796,307?

The Orange Book status must be assessed against the current patent listing for the relevant Arcapta Neohaler NDA and any later FDA delisting or expiration updates. A patent’s existence does not by itself prove that it remains listed in the Orange Book.

For an ANDA applicant, the regulatory consequences depend on whether the patent is listed for the reference product and whether the applicant submits:

Paragraph I certification;
Paragraph II certification;
Paragraph III certification; or
Paragraph IV certification.

A Paragraph IV certification alleging that the listed patent is invalid, unenforceable, or not infringed can trigger notice and potential patent litigation. If the NDA holder or patent owner brings suit within the statutory period, FDA approval may be subject to a 30-month stay, subject to applicable statutory exceptions and court rulings (21 U.S.C. § 355).

Are Paragraph IV challenges likely to target this patent?

A generic indacaterol applicant would likely evaluate US 8,796,307 together with compound, formulation, method-of-use, and device patents. The patent is particularly relevant if the ANDA product uses:

Indacaterol maleate;
A dry powder;
A capsule;
A daily dose within the claimed range;
A pharmaceutically acceptable carrier.

A Paragraph IV strategy could attack the patent on several grounds:

Non-infringement

The applicant could argue that its product is not in capsule form, does not contain the claimed salt or solvate, does not use a dry powder, or falls outside the claimed dose range.

Invalidity

Potential validity theories would depend on the complete specification and prosecution history. They could include anticipation, obviousness, lack of written description, enablement, indefiniteness, or improper claim scope. The claim set’s focus on a known active ingredient in a capsule formulation makes the technical disclosures and priority date important to any obviousness analysis.

Regulatory design-around

A generic could pursue a different delivery system, such as a multidose device or nebulized formulation. That approach may reduce exposure to these capsule claims but could encounter separate patents covering the active ingredient, inhaler, particle engineering, formulation, or method of treatment.

What other patents are likely to matter for indacaterol?

The indacaterol estate is expected to include more than one patent family. A complete freedom-to-operate review should distinguish the following categories.

Compound patents

Compound patents protect indacaterol or related beta-2 agonist chemical structures. These patents generally create the earliest and most important barrier to generic entry. If still enforceable, they can block products regardless of whether the generic uses a capsule or a different inhaler.

Salt and solid-state patents

Indacaterol maleate, polymorphs, hydrates, solvates, crystal forms, and particle properties may be protected by separate claims. These patents can be important where a generic uses the same maleate form but argues that the formulation patent does not apply.

Formulation patents

US 8,796,307 is in this category. Its principal commercial value is the combination of active ingredient, carrier, capsule, inhalation, dry powder, and dose.

Device patents

The Neohaler device and capsule-piercing mechanism may be subject to separate patents. Device claims can create exposure even when a generic avoids a composition patent by using a different inhaler architecture.

Method-of-use patents

Indacaterol treatment methods may be protected by claims directed to chronic obstructive pulmonary disease, once-daily administration, bronchodilation, or combinations with other respiratory agents. Method-of-use patents are relevant to ANDA labeling and induced-infringement analysis.

Manufacturing patents

Manufacturing claims may cover synthesis of indacaterol, resolution of the R-enantiomer, preparation of indacaterol maleate, crystallization, micronization, blending, and capsule filling. These patents may not prevent sale of a non-infringing finished dosage form if the generic uses an independent process, but they can create supply-chain risk.

How strong is the patent estate represented by US 8,796,307?

The patent has meaningful product-level coverage but a narrower perimeter than a compound patent.

Strengths

It directly maps to the Arcapta capsule dosage form.
Claim 1 covers indacaterol salts and solvates, not only maleate.
The open “comprising” language permits additional excipients and ingredients.
Claims 2 through 5 capture the commercial inhalation and dry-powder configuration.
Claim 7 closely tracks a 75-microgram indacaterol maleate product.

Limitations

The capsule requirement limits coverage of non-capsule delivery systems.
The inhalable and dry-powder limitations narrow claims 2 through 5.
The claims provided do not expressly recite a specific inhaler device.
A competing formulation may avoid the claims by using a non-capsule dosage form, a different active form, or a dose outside the stated range.
Validity depends on the full specification, prosecution history, priority chain, and prior art, none of which are established by the claim text alone.

Which companies are challenging indacaterol exclusivity?

The supplied record does not identify a specific ANDA applicant, Paragraph IV notice, patent litigation docket, or settlement agreement involving US 8,796,307. No company-specific challenge or settlement should be attributed to this patent without a verified FDA, court, or SEC source.

The competitive field includes originator and generic respiratory companies capable of developing indacaterol or LABA inhalation products. Commercial entry will depend on the complete patent estate, FDA-listed patents, product-specific bioequivalence requirements, device compatibility, and any litigation outcome.

What generic launch scenarios exist?

Scenario	Commercial result
Generic duplicates indacaterol maleate capsule dry powder	Highest exposure to claims 1 through 7
Generic uses a different capsule carrier	Likely remains exposed because carrier identity is not specifically limited
Generic uses a capsule but changes dose	May avoid claims 5 and 7 but not necessarily claims 1 or 6
Generic uses a multidose reservoir inhaler	May avoid the capsule claims, subject to other patents
Generic uses a nebulized solution	May avoid the dry-powder and capsule limitations
Generic challenges listed patents under Paragraph IV	Possible early approval subject to litigation and statutory stays
Generic waits for patent expiration	Lower litigation risk but later market entry

Key Takeaways

US 8,796,307 is a formulation patent covering indacaterol compositions in capsule form.
Claims 2 through 5 focus on inhalable dry-powder products.
Claims 6 and 7 specifically cover indacaterol maleate.
Claim 7 most closely corresponds to a 75-microgram Arcapta Neohaler capsule.
The open “comprising” language limits design-around opportunities based only on excipient changes.
The capsule requirement creates a meaningful design-around route through multidose, metered-dose, or nebulized delivery systems.
The patent’s ordinary term is expected to extend into approximately 2026, subject to the official USPTO patent-term-adjustment calculation.
FDA exclusivity and patent exclusivity are separate. The five-year NCE period for indacaterol expired before the expected patent expiration.
The complete generic-entry analysis requires review of compound, salt, formulation, device, method-of-use, manufacturing, and Orange Book-listed patents as a single estate.
The supplied record does not establish a specific Paragraph IV challenger, litigation outcome, or settlement agreement.

References

Food and Drug Administration. (2011). Arcapta Neohaler (indacaterol maleate) inhalation powder prescribing information. U.S. Department of Health and Human Services.
United States Patent and Trademark Office. (2014). U.S. Patent No. 8,796,307: Pharmaceutical composition. U.S. Department of Commerce.
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355.
United States Patent and Trademark Office. (n.d.). Patent term adjustment and patent term calculation guidance. U.S. Department of Commerce.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	9913083.3	Apr 6, 1999

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1183240	⤷ Start Trial	C300437	Netherlands	⤷ Start Trial
European Patent Office	1183240	⤷ Start Trial	CA 2010 00006	Denmark	⤷ Start Trial
European Patent Office	1183240	⤷ Start Trial	91651	Luxembourg	⤷ Start Trial
European Patent Office	1183240	⤷ Start Trial	SPC009/2010	Ireland	⤷ Start Trial
European Patent Office	1183240	⤷ Start Trial	10C0006	France	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,796,307

Summary for Patent: 8,796,307